Food & Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food & Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Crucell N.V.
PER.C6-produced HIV vaccine to advance to next phase of clinical trials
September 24th, 2004
At the AIDS Vaccine 2004 conference in Lausanne, Switzerland, Merck & Co.'s executive director for vaccine research Robin Isaacs announced that one of Merck's candidate HIV vaccines, produced with Crucell's PER.C6 technology, will advance to its next phase of clinical trials in the near future. The HIV vaccine that Merck intends to advance to the next phase of clinical development is based on a recombinant adenovirus and is produced on Crucell's proprietary PER.C6 cell technology to facilitate the industrial-scale manufacturing of a vaccine to meet global demand. Crucell and Merck signed an agreement in October 2000, granting Merck an exclusive...
Source: Food & Drug Law Weekly (2004-09-24)
|
